A plethora of cases have identified a temporal link between COVID-19 and cFSGS, particularly in the African-American population, with a higher incidence and poorer prognosis among high-risk apolipoprotein L1 (APOL1) variants (36, 37, 55, 125, 222, 235, 237, 271, 275–303). The gene discussed is APOL1; the disease is COVID-19.